Overview

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML. The safety of this treatment will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aldesleukin
Antilymphocyte Serum
Busulfan
Fludarabine
Fludarabine phosphate
Interleukin-2
Methotrexate
Tacrolimus
Thymoglobulin
Vidarabine